Omnicell, Inc. (OMCL)
NASDAQ: OMCL · Real-Time Price · USD
45.78
+0.21 (0.46%)
At close: Dec 24, 2025, 1:00 PM EST
45.50
-0.28 (-0.61%)
After-hours: Dec 24, 2025, 4:53 PM EST
Omnicell Revenue
Omnicell had revenue of $310.63M in the quarter ending September 30, 2025, with 9.99% growth. This brings the company's revenue in the last twelve months to $1.18B, up 10.67% year-over-year. In the year 2024, Omnicell had annual revenue of $1.11B, down -3.04%.
Revenue (ttm)
$1.18B
Revenue Growth
+10.67%
P/S Ratio
1.80
Revenue / Employee
$320,910
Employees
3,670
Market Cap
2.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.11B | -34.87M | -3.04% |
| Dec 31, 2023 | 1.15B | -148.84M | -11.48% |
| Dec 31, 2022 | 1.30B | 163.93M | 14.48% |
| Dec 31, 2021 | 1.13B | 239.81M | 26.88% |
| Dec 31, 2020 | 892.21M | -4.82M | -0.54% |
| Dec 31, 2019 | 897.03M | 109.72M | 13.94% |
| Dec 31, 2018 | 787.31M | 74.60M | 10.47% |
| Dec 31, 2017 | 712.71M | 16.81M | 2.41% |
| Dec 31, 2016 | 695.91M | 211.35M | 43.62% |
| Dec 31, 2015 | 484.56M | 43.66M | 9.90% |
| Dec 31, 2014 | 440.90M | 60.32M | 15.85% |
| Dec 31, 2013 | 380.59M | 66.56M | 21.19% |
| Dec 31, 2012 | 314.03M | 68.49M | 27.90% |
| Dec 31, 2011 | 245.54M | 23.13M | 10.40% |
| Dec 31, 2010 | 222.41M | 8.95M | 4.19% |
| Dec 31, 2009 | 213.46M | -38.41M | -15.25% |
| Dec 31, 2008 | 251.87M | 38.78M | 18.20% |
| Dec 31, 2007 | 213.08M | 58.37M | 37.73% |
| Dec 31, 2006 | 154.71M | 33.19M | 27.31% |
| Dec 31, 2005 | 121.52M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OMCL News
- 15 days ago - Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript - Seeking Alpha
- 16 days ago - Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management - Business Wire
- 23 days ago - Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show - Business Wire
- 4 weeks ago - Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 5 weeks ago - Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies - Business Wire
- 7 weeks ago - Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Omnicell Announces Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Omnicell to Release Third Quarter 2025 Financial Results on October 30, 2025 - Business Wire